ERBB2 and breast carcinoma: Previously, the results from a multicenter, retrospective, medical chart review study (ROSET-BM) suggested robust effectiveness of trastuzumab deruxtecan (T-DXd) in patients with HER2+ breast cancer with BM in real world practice [2].